2021 (17 POSTS)

Proctor DM, Bhat V, Suh M, Reichert H, Jiang X, Thompson CM. 2021. Inhalation cancer risk assessment for environmental exposure to hexavalent chromium: Comparison of margin-of-exposure and linear extrapolation approaches. Regul Toxicol Pharmacol 124(August):104969; doi: 10.1016/j.yrtph.2021.104969. PMID: 34089813.

View Abstract

Ierardi AM, Lotter JT, Jacobs N, Finley BL, Pierce JS. Derivation of a proposed asbestiform tremolite NOAEL for lung cancer. Virtual poster Presentation at Society of Toxicology 60th Annual Meeting, Virtual, 2021.

Chappell GA, Wikoff DS, Thompson CM. 2021. Assessment of mechanistic data for hexavalent chromium-induced rodent intestinal cancer using the key characteristics of carcinogens. Toxicol Sci 180(1):38–50; doi: 10.1093/toxsci/kfaa187. PMID: 33404626.

View Abstract

Hathway J, Miller-Wilson L, Yao W, Jensen I, Weinstein M, Parks P. 2021. The health economic impact of varying levels of adherence to colorectal screening on providers and payers. J Med Econ 24(1):69–78; doi: 10.1080/13696998.2020.1858607. PMID: 33970747.

View Abstract

2020 (27 POSTS)

Li S, Liu J, Gong T, Guo H, Gawade PL, Kelsh MA, et al. 2020. Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer. J Geriatr Oncol 11(8):1309–1315; doi: 10.1016/j.jgo.2020.06.018. PMID: 32624415.

View Abstract

Ravandi F, Pierce S, Garcia-Manero G, Kadia T, Jabbour E, Borthakur G, … Kelsh M, et al. 2020. Salvage therapy outcomes in a historical cohort of patients with relapsed or refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 20(11):e871–e882; doi: 10.1016/j.clml.2020.06.007. PMID: 32792304.

View Abstract

Gentry R, Thompson CM, Franzen A, Salley J, Albertini R, Lu K, Greene T. 2020. Using mechanistic information to support evidence integration and synthesis: A case study with inhaled formaldehyde and leukemia. Crit Rev Toxicol 50(10):885–918; doi: 10.1080/10408444.2020.1854678. PMID: 33538218.

View Abstract

Saldanha G, Ording AG, Bylsma LC, Darvalics B, Solis D, Tang JY, Sorensen HT, Fryzek J. 2020. High frequency basal cell carcinoma (BCC) in Danish patients: Prevalence and consistency. J Eur Acad Dermatol Venereol 34(10):e646-e648; doi: 10.1111/jdv.16512. PMID: 32314479.

View Abstract

Levin-Sparenberg E, Bylsma LC, Lowe K, Sangare L, Fryzek JP, Alexander DD. 2020. A systematic literature review and meta-analysis describing the prevalence of KRAS, NRAS, and BRAF gene mutations in metastatic colorectal cancer. Gastroenterol Res 13(5):184–198; doi: 10.14740/gr1167. PMID: 33224365.

View Abstract

Li S, Peng Y, Liu J, Li S, Raskin L, Kelsh MA, et al. 2020. Variations in hospitalization and emergency department/observation stays using the oncology care model methodology in Medicare data. Curr Med Res Opin 36(9):1519–1527; doi: 10.1080/03007995.2020.1801403. PMID: 32715807.

View Abstract

Gawade PL, Li S, Henry D, Smith N, Belani R, Kelsh MA, et al. 2020. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. Support Care Cancer 28(9):4413–4424; doi: 10.1007/s00520-020-05295-2. PMID: 31919669.

View Abstract

Locatelli F, Whitlock JA, Peters C, Chen-Santel C, Chia V, Dennis RM, … Kelsh MA, et al. 2020. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia 34(9):2473–2478; doi: 10.1038/s41375-020-0770-8. PMID: 32094465.

View Abstract

Dronin-Fenton D, Dalvi T, Movva N, Pedersen I, Hansen H, Fryzek J, Mellemgaard A, Rasmussen T, et al. PD-L1 expression and survival in stage III unresectable non-small cell lung cancer patients in Denmark. Abstract #2865, European Society for Medical Oncology (ESMO), Virtual, August 2020.

View Abstract

Lafranconi M, Budinsky R, Corey L, Haws L, Klapacz J, Chappell G, Golden R. Exposure to 1,4-dioxane above the metabolic saturation threshold induces a mitogenic key element in the mouse liver cancer mode of action. Abstract #1505. Society of Toxicology 59th Annual Meeting, Virtual, 2020.

View Abstract

Jackson C, Choi J, Khalafallah AM, Price C, Bettegowda C, Lim M, et al. 2020. A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma. J Neuro-Oncol 148(3):419–431; doi: 10.1007/s11060-020-03556-y. PMID: 32562247.

View Abstract

Elbeddini A, Hooda N, Gazarin M, Webster P, McMillan J. 2020. Irinotecan-associated dysarthria in patients with pancreatic cancer: A single site experience. Am J Case Rep 21:e924058; doi: 10.12659/AJCR.924058. PMID: 32594093.

View Abstract

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Jena A, et al. 2020. Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives. J Med Econ 23(6):581-592; doi: 10.1080/13696998.2020.1730123. PMID: 32063100.

View Abstract

Botros D, Dux H, Price C, Khalafallah AM, Mukherjee D. 2020. Assessing the efficacy of repeat resections in recurrent glioblastoma: A systematic review. Neurosurg Rev 44:1259–1271; doi: 10.1007/s10143-020-01331-1. PMID: 32533385.

View Abstract

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Yao W, et al. Budget impact of improving adherence to colorectal cancer screening. Abstract PCN148, ISPOR 2020.

View Abstract

Hathway J, Miller-Wilson L, Jensen I, Ozbay B, Regan C, Yao W, et al. The impact of increasing mt-sDNA use among colorectal cancer screeners in a US employer population. Abstract PCN145, ISPOR 2020.

View Abstract